Canada Vigilance Adverse Reaction Reporting Form

Report of suspected adverse reactions to marketed health products in Canada

			, ,	d confidentiality on Page 2. tion as possible for the remaining items.	PROTECTED WHEN COMPLETED - B	
A. Patient Inform				C. Suspected Health Prod		
1. Identifier						
2. Age	3. Sex*	4. Height	5. Weight	1. Name*, strength and manufacturer (if known)		
Years	☐ Male	cm	kg			
Months	Female	feet	lbs	#2		
B. Adverse Read	tion			"2		
		maction (Select a	Il that anniv)	2. Dose, frequency and route used		
1. Outcome attributed to adverse reaction (Select all that apply) Death: (yyyy-mm-dd) Disability				#1	#2	
Life-threatening						
Hospitalization Required intervention to prevent damage/impairment			intervention to	3. Therapy dates (or duration)		
Hospitalization - pr	olonged	Other:	amago/impairment	#1 From (yyyy-mm-dd) - To (yyyy-mm-dd)	#2 From (yyyy-mm-dd) - To (yyyy-mm-dd	
2. Reaction date (yyyy		3. Report dat	e (yyyy-mm-dd)			
	•			4. indication for use		
4. Describe reaction or problem*				#1	#2	
				5. Reaction abated after use stopp		
				#1 Yes No Does not apply		
				6. Lot #	7. Expiration #1 (yyyy-mm-dd)	
					#2 (vvvv-mm-dd)	
				#2 8. Reaction reappeared after reintre	,	
					#2 Yes No Does not apply	
5. Relevant tests/labor	atory data (i	including dates (vvv	/-mm-dd))	9. Concomitant health products, ex (name, dose, frequency, route used a second	and therapy dates (yyyy-mm-dd))	
6. Relevant history and (e.g. allergies, pregnar	d pre-existir ncy, smoking/a	ng medical condit alcohol use, hepatic	lons (renal dysfunction)	D. Reporter Information 1. Name*, occupation, address, tele	phone number⁴	
				2. Health professional? 3.	Reported to manufacturer?	

^{**} As per the Treasury Board of Canada Secretariat Government Security Policy.





Yes No

☐Yes ☐No

Instructions to Complete the Canada Vigilance Adverse Reaction Reporting Form

- Use this form only to report adverse reactions to Canadian marketed health products, including prescription and non-prescription medications; natural health products; biologically derived products such as vaccines and fractionated blood products; cells, tissues and organs; radiopharmaceuticals; and disinfectants and sanitizers with disinfectant claims.
- All sections of the form should be filled in as completely as possible. Use a separate form for each patient. Up to two suspected health products for
 a particular adverse reaction may be reported on one form. Attach an additional form if there are more than two suspected health products for the
 adverse reaction being reported. Additional pages may be attached if more space is required.
- For the "Identifier" box, provide some type of identifier that will allow you, the reporter, to readily locate the case if you are contacted for more information; do not use the patient's name. See the Confidentiality disclaimer at the bottom of this page.
- Any follow-up information for an adverse reaction that has already been reported can be submitted using a new form, indicating that it consists of
 follow-up information, including, if known, the date of the original report and the Adverse Reaction Number provided in the acknowledgement letter.
- Reports can be faxed to 1-866-678-6789 (toll-free) or mailed to: Canada Vigilance Program, Marketed Health Products Directorate, Health
 Canada, Postal Locator 0701E, Ottawa, Ontario K1A 0K9. Postage paid labels are available at www.health.gc.ca/medeffect or by calling
 1-866-234-2345 (toll-free). Do not send reports by e-mail.

Information on Adverse Reaction Reporting

What is an adverse reaction?

An adverse reaction is a harmful and unintended response to a health product. This includes any undesirable patient effect suspected to be associated with health product use. Unintended effect, health product abuse, overdose, interaction (including drug-drug and drug-food interactions) and unusual lack of therapeutic efficacy are all considered to be reportable adverse reactions.

A serious adverse reaction is one that requires in-patient hospitalization or prolongation of existing hospitalization, causes congenital malformation, results in persistent or significant disability or incapacity, is life-threatening or results in death. Adverse reactions that require significant medical intervention to prevent one of these listed outcomes are also considered to be serious.

Which adverse reactions should be reported?

All suspected adverse reactions should be reported, especially those that are:

- · unexpected, regardless of their severity, i.e., not consistent with product information or labelling; or
- · serious, whether expected or not; or
- reactions to recently marketed health products (on the market for less than five years), regardless of their nature or severity.

Alternative ways to report

You can also report side effects to health products to the Canada Vigilance Program:

- By calling 1-866-234-2345 (toll-free)
- · Online: www.health.gc.ca/medeffect

The Canada Vigilance Adverse Reaction Reporting Form is also available online at www.health.gc.ca/medeffect or at the back of the Compendium of Pharmaceuticals and Specialties (CPS).

Other Information

- Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the adverse reaction.
- Adverse reaction reports are, for the most part, only suspected associations. A temporal or possible association is sufficient for a report to be made.
 Reporting of an adverse reaction does not imply a definitive causal link.
- Health professionals and consumers may also report adverse reactions to the market authorization holder (MAH). Indicate on your adverse reaction
 report sent to Health Canada if a case was also reported to the product's MAH.

For additional information, contact a Canada Vigiliance Regional Office by telephone at 1-866-234-2345 (toll-free) or:

Canada Vigilance Regional Office – British Columbia and Yukon 400-4595 Canada Way, Burnaby, BC V5G 1J9 Canada Vigilance_BC@hc-sc.gc.ca

Canada Vigilance Regional Office – Alberta and Northwest Territories Suite 730, 9700 Jasper Ave, Edmonton, AB T5J 4C3 CanadaVigilance_AB@hc-sc.gc.ca

Canada Vigilance Regional Office – Saskatchewan 101 - 22nd Street East, Saskatoon, SK S7K 0E1 CanadaVigilance_SK@hc-sc.gc.ca

Canada Vigilance Regional Office - Manitoba 510 Lagimodière Blvd, Winnipeg, MB R2J 3Y1 CanadaVigilance_MB@hc-sc.gc.ca Canada Vigilance Regional Office - Ontario and Nunavut 2301 Midland Ave, Toronto, ON M1P 4R7 Canada Vigilance_ON@hc-sc.gc.ca

Canada Vigilance Regional Office – Québec Suite 202-40, East Tower 200 René-Lévesque Blvd. West, Montréai, QC H2Z 1X4 CanadaVigilance_QC@hc-sc.gc.ca

For New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador:

Canada Vigilance Regional Office - Atlantic Suite 1625, 1505 Barrington St., Halifax, NS B3J 3Y6 Canada Vigilance_ATL@hc-sc.gc.ca

Confidentiality

Personal information collected, used or disclosed under the Canada Vigilance Program is confidential and protected. For the purposes of the Canada Vigilance Program, information related to the identity of a patient and/or reporter of the adverse reaction will be protected as personal information under the Privacy Act, and under the Access to Information Act, in the case of an access to information request. Provision of the information requested on this form is voluntary. Information from adverse reaction reports is maintained in a computerized database and used for the monitoring of marketed health products, which may contribute to the detection of potential product-related safety issues, as well as to the benefit-risk assessments of these products. For details about personal information collected under this program, visit the Government of Canada web site on Institution-Specific Personal Information Banks under Health Canada, Health Products and Food Branch, Branch Incident Reporting System, PIB # ppu 088 at: http://infosource.gc.ca/inst/shc/fed07-eng.asp (Health Products and Food Branch, Branch Incident Reporting System).